Axonics, Inc. (NASDAQ:AXNX) Given Consensus Rating of “Hold” by Analysts

Shares of Axonics, Inc. (NASDAQ:AXNX) have received a consensus rating of “Hold” from the ten analysts that are covering the firm, MarketBeat reports. Eight research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $69.57.

Separately, Needham & Company LLC reissued a “hold” rating on shares of Axonics in a report on Monday, August 5th.

Axonics Stock Up 0.1 %

Shares of AXNX opened at $69.48 on Thursday. The business’s fifty day moving average is $68.87 and its 200 day moving average is $68.03. Axonics has a 12-month low of $48.30 and a 12-month high of $69.91. The stock has a market cap of $3.54 billion, a P/E ratio of -217.13 and a beta of 0.81.

Axonics (NASDAQ:AXNX) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.10 by $0.03. The firm had revenue of $114.57 million for the quarter, compared to analyst estimates of $112.83 million. Axonics had a negative net margin of 0.42% and a negative return on equity of 0.27%. The business’s quarterly revenue was up 23.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.15) earnings per share. On average, analysts expect that Axonics will post 0.24 EPS for the current year.

Institutional Trading of Axonics

A number of institutional investors and hedge funds have recently modified their holdings of AXNX. Principal Financial Group Inc. grew its stake in Axonics by 461.1% in the 4th quarter. Principal Financial Group Inc. now owns 65,668 shares of the company’s stock valued at $4,087,000 after purchasing an additional 53,965 shares during the period. Edgestream Partners L.P. bought a new position in Axonics during the first quarter valued at about $605,000. Janus Henderson Group PLC grew its position in Axonics by 637.7% during the first quarter. Janus Henderson Group PLC now owns 178,322 shares of the company’s stock valued at $12,298,000 after buying an additional 154,149 shares during the period. Artisan Partners Limited Partnership increased its holdings in Axonics by 91.7% during the fourth quarter. Artisan Partners Limited Partnership now owns 1,220,889 shares of the company’s stock worth $75,976,000 after buying an additional 583,958 shares during the last quarter. Finally, Gabelli Funds LLC bought a new stake in Axonics in the first quarter worth about $12,271,000. 99.48% of the stock is owned by hedge funds and other institutional investors.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.